Intraperitoneal Lymphokine-Activated Killer Cell/Interleukin-2 Therapy in Patients With Intra- abdominal Cancer: Immunologic Considerations
Walter J. Urba(Providence Portland Medical Center), Dan L. Longo(Harvard University), John W. Smith(SUNY Upstate Medical University), Helen Rager(Frederick National Laboratory for Cancer Research), Michael A. Bookman(National Cancer Institute), Jeffrey W. Clark(Massachusetts General Hospital), Ronald G. Steis, Jeffrey L. Rossio(Frederick National Laboratory for Cancer Research), John R. Ortaldo(Frederick National Laboratory for Cancer Research), Annette E. Maluish(Frederick National Laboratory for Cancer Research), Suzanne K. Beckner
Cited by 51
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers
|Journal of Clinical Oncology|2012|1.6k